The FDA has published its Biosimilar User Fee Act (BsUFA) rates for 2018. The Biosimilar User Fee Amendments of 2017 (BsUFA II) authorize the agency to assess and collect fees from applicants for biosimilar products from October 2017 to September 2022.
The FDA has published its Biosimilar User Fee Act (BsUFA) rates for 2018. The Biosimilar User Fee Amendments of 2017 (BsUFA II) authorize the agency to assess and collect fees from applicants for biosimilar products from October 2017 to September 2022. The FDA uses the fees to expedite the review process for biosimilars.
Some of the 2018 rates represent substantial increases from those charged in 2017:
However, application fees will see some reductions:
The 2018 fees include a new program fee of $304,162, but eliminates 2 fee categories: product fees ($97,750) and establishment fees ($512,200).
The agency also released its performance goals for the coming year. The agency plans to review and act on:
The agency also has plans to improve its performance with respect to original manufacturing supplements. In 2018, its goal is to review and act on 70% of manufacturing supplements requiring prior approval within 4 months of receipt. That percentage will increase by 5% per year until 2022, when the FDA plans to act on 90% of such supplements within the same timeframe. Manufacturing supplements that do not require prior approval will be reviewed, across all years from 2018 to 2022, within 6 months of receipt.
The FDA will also implement its program for enhanced review transparency and communication for original 351 Biologics License Applications. According to the FDA, the program is designed to promote efficiency and effectiveness of the first review cycle process for biosimilars, and to minimize the number of review cycles needed for an approval. Under the program, the FDA review team and the biosimilar applicant may follow a standard communication approach, or may reach a mutual agreement on the timing and nature of interaction and the information exchange between the 2 parties.
Under a standard approach, the agency will hold a presubmission meeting with the applicant to discuss the planned content of the application, the applicant will submit an original application, and the FDA will communicate substantive review issues in its Day 74 letter (or notify the applicant if no substantive review issues were identified). The BsUFA review period will begin at the end of the 60-day filing review period beginning on the day of the FDA’s receipt of the original submission. The FDA will communicate with the applicant mid-cycle in the review process to provide an update on the review’s status, and will also meet with the applicant late in the cycle. For applications that will be subject to an advisory committee meeting, the FDA plans to convene meetings not later than 2 months prior to the BsUFA goal date. The FDA plans to complete all inspections for applications in each program within 10 months of having received an application.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Eye on Pharma: BI Cyltezo Partnership; Europe Ustekinumab Launch; Mexico Biosimilar Approval
July 24th 2024Boehringer Ingelheim (BI) partners with GoodRx to offer its unbranded adalimumab biosimilar to patients at an exclusive low price; a new ustekinumab biosimilar launches in Europe; and Mexican officials approve a bevacizumab biosimilar.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Real-World Study: No Increase in Health Resource Costs After Infliximab Biosimilar Introduction
July 20th 2024Although biosimilars reduce drug purchasing costs for hospitals, it’s unclear whether those savings might be offset by increased health resource utilization following a non-medical switching initiative.